Major or Mild Neurocognitive Disorder Due to Alzheimer Disease

  • Ana Hategan
  • Glen L. Xiong


Major or mild neurocognitive disorder (NCD) due to Alzheimer disease is an acquired cognitive decline with an insidious onset and gradual progression. Major and mild NCDs exist on a spectrum of cognitive and functional impairment. A decline in one or more cognitive domains, along with a concern about cognition on the part of the patient, a knowledgeable informant, or the clinician, and performance on an objective assessment that falls below the expected level or that has been observed to decline over time represent core features of major or mild NCD. The cognitive impairment is commonly accompanied, and occasionally preceded, by neuropsychiatric symptoms, described as deterioration in emotional control, social behavior, or motivation, which are described elsewhere. This chapter reviews the diagnostic guidelines, typical and atypical clinical presentations, differential diagnosis, and treatment considerations in Alzheimer-related NCD.


Alzheimer disease Alzheimer dementia Major or mild neurocognitive disorder Neurocognitive disorder due to Alzheimer disease Atypical Alzheimer disease Cognitive impairment Amnestic phenotype 


  1. 1.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.CrossRefGoogle Scholar
  2. 2.
    Nowrangi MA, Lyketsos CG, Rosenberg PB. Principles and management of neuropsychiatric symptoms in Alzheimer’s dementia. Alzheimers Res Ther. 2015;7(1):12.–015–0096–3.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Budson AE, Solomon PR. New diagnostic criteria for Alzheimer’s disease and mild cognitive impairment for the practical neurologist. Pract Neurol. 2012;12:88–96.CrossRefPubMedGoogle Scholar
  4. 4.
    Marshall GA, Amariglio RE, Sperling RA, Rentz DM. Activities of daily living: where do they fit in the diagnosis of Alzheimer’s disease? Neurodegener Dis Manag. 2012;2(5):483–91.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on aging Alzheimer’s disease centers, 2005–2010. J Neuropathol Exp Neurol. 2012;71(4):266–73.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Molin P, Rockwood K. The new criteria for Alzheimer’s disease—implications for geriatricians. Can Geriatr J. 2016;19(2):66–73.PubMedPubMedCentralGoogle Scholar
  7. 7.
    World Health Organization. International classification of diseases (ICD-11). January 2017. Accessed 12 Nov 2017.
  8. 8.
    Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614–29.CrossRefPubMedGoogle Scholar
  9. 9.
    Blennow K, de Leon MJ, Zetterberg H. Alzheimer’s disease. Lancet. 2006;368(9533):387–403.CrossRefPubMedGoogle Scholar
  10. 10.
    Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9(1):63–75.e2.CrossRefPubMedGoogle Scholar
  11. 11.
    Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374:523–32.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Campion D, Dumanchin C, Hannequin D, et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet. 1999;65:664–70.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Selkoe DJ. Alzheimer’s disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–66.CrossRefPubMedGoogle Scholar
  15. 15.
    Rademakers R, Cruts M, Van Broeckhoven C. Genetics of early-onset Alzheimer dementia. ScientificWorldJournal. 2003;3:497–519.CrossRefPubMedGoogle Scholar
  16. 16.
    Brickell KL, Steinbart EJ, Rumbaugh M, et al. Early-onset Alzheimer disease in families with late-onset Alzheimer disease: a potential important subtype of familial Alzheimer disease. Arch Neurol. 2006;63:1307–11.CrossRefPubMedGoogle Scholar
  17. 17.
    Nochlin D, van Belle G, Bird TD, Sumi SM. Comparison of the severity of neuropathologic changes in familial and sporadic Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1993;7:212–22.PubMedGoogle Scholar
  18. 18.
    Querfurth HW, LaFerla FM. Alzheimer’s disease. N Engl J Med. 2010;362(4):329–44.CrossRefPubMedGoogle Scholar
  19. 19.
    Iturria-Medina Y, Sotero RC, Toussaint PJ, Mateos-Perez JM, Evans AC, The Alzheimer’s Disease Neuroimaging Initiative. Early role of vascular dysregulation on late-onset Alzheimer’s disease based on multifactorial data-driven analysis. Nat Commun. 2016;7:11934. Scholar
  20. 20.
    Jones DT, Knopman DS, Gunter JL, et al., Alzheimer’s Disease Neuroimaging Initiative. Cascading network failure across the Alzheimer’s disease spectrum. Brain. 2016;139(Pt 2):547–62.Google Scholar
  21. 21.
    Zeppenfeld DM, Simon M, Haswell JD, et al. Association of perivascular localization of aquaporin-4 with cognition and Alzheimer disease in aging brains. JAMA Neurol. 2017;74(1):91–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Borenstein AR, Copenhaver CI, Mortimer JA. Early-life risk factors for Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(1):63–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Harris SA, Harris EA. Herpes simplex virus type 1 and other pathogens are key causative factors in sporadic Alzheimer’s disease. J Alzheimers Dis. 2015;48(2):319–53.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Patterson C, Feightner JW, Garcia A, G-YR H, MacKnight C, Sadovnick AD. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. Can Med Assoc J. 2008;178(5):548–56.CrossRefGoogle Scholar
  25. 25.
    Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC. Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: the Cache County Study. Arch Gen Psychiatry. 2004;61:518–24.CrossRefPubMedGoogle Scholar
  26. 26.
    Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol. 1998;150(2):296–304.CrossRefPubMedGoogle Scholar
  27. 27.
    de la Torre JC, Stefano GB. Evidence that Alzheimer’s disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res Brain Res Rev. 2000;34(3):119–36.CrossRefPubMedGoogle Scholar
  28. 28.
    Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.CrossRefPubMedGoogle Scholar
  29. 29.
    Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry. 2006;63(5):530–8.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Ojo O, Brooke J. Evaluating the association between diabetes, cognitive decline and dementia. Int J Environ Res Public Health. 2015;12(7):8281–94.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Petersson SD, Philippou E. Mediterranean diet, cognitive function, and dementia: a systematic review of the evidence. Adv Nutr. 2016;7(5):889–904.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;(1):CD003160.
  33. 33.
    Petersen RC, Smith GE, Waing SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Jalbert JJ, Daiellio LA, Lapane KL. Dementia of the Alzheimer type. Epidemiol Rev. 2008;30:15–34.CrossRefPubMedGoogle Scholar
  35. 35.
    Schmidt C, Wolff M, Weitz M, Bartlau T, Korth C, Zerr I. Rapidly progressive Alzheimer disease. Arch Neurol. 2011;68(9):1124–30.CrossRefPubMedGoogle Scholar
  36. 36.
    Gauthier S, Patterson C, Chertkow H, et al. Recommendations of the 4th Canadian consensus conference on the diagnosis and treatment of dementia (CCCDTD4). Can Geriatr J. 2012;15(4):120–6.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Doraiswamy PM, Steffens DC, Pitchumoni S, Tabrizi S. Early recognition of Alzheimer’s disease: what is consensual? What is controversial? What is practical? J Clin Psychiatry. 1998;59(Suppl 13):6–18.PubMedGoogle Scholar
  38. 38.
    Chapman FM, Dickinson J, McKeith I, Ballard C. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer’s disease: treatment implications. Am J Psychiatry. 1999;156(12):1983–5.PubMedGoogle Scholar
  39. 39.
    Dufouil C, Clayton D, Brayne C, et al. Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-mental state examination. Neurology. 2000;55(11):1609–13.CrossRefPubMedGoogle Scholar
  40. 40.
    Han L, Cole M, Bellavance F, McCusker J, Primeau F. Tracking cognitive decline in Alzheimer’s disease using the mini-mental state examination: a meta-analysis. Int Psychogeriatr. 2000;12(2):231–47.CrossRefPubMedGoogle Scholar
  41. 41.
    Montreal Cognitive Assessment. Accessed 28 Oct 2016.
  42. 42.
    Klunk WE. Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk-prediction for Alzheimer dementia. Neurobiol Aging. 2011;32(Suppl 1):S20–36.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kapogiannis D, Boxer A, Schwartz JB, et al. Dysfunctionally phosphorylated type 1 insulin receptor substrate in neural-derived blood exosomes of preclinical Alzheimer’s disease. FASEB J. 2015;29(2):589–96.CrossRefPubMedGoogle Scholar
  44. 44.
    Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2001;56(9):1143–53.CrossRefPubMedGoogle Scholar
  45. 45.
    Schott JM, Warren JD. Alzheimer’s disease: mimics and chameleons. Pract Neurol. 2012;12(6):358–66.CrossRefPubMedGoogle Scholar
  46. 46.
    Rogan S, Lippa CF. Alzheimer’s disease and other dementias: a review. Am J Alzheimers Dis Other Demen. 2002;17:11–7.Google Scholar
  47. 47.
    Grossberg GT, Lake JT. The role of the psychiatrist in Alzheimer’s disease. J Clin Psychiatry. 1998;59(Suppl 9):3–6.PubMedGoogle Scholar
  48. 48.
    Dubinsky RM, Stein AC, Lyons K. Practice parameter: risk of driving and Alzheimer’s disease (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000;54(12):2205–11.CrossRefPubMedGoogle Scholar
  49. 49.
    Massoud F, Leger G. Pharmacological treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):579–88.Google Scholar
  50. 50.
    Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer disease. Arch Neurol. 2011;68(8):991–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317–24.CrossRefPubMedGoogle Scholar
  52. 52.
    Jones HE, Joshi A, Shenkin S, Mead GE. The effect of treatment with selective serotonin reuptake inhibitors in comparison to placebo in the progression of dementia: a systematic review and meta-analysis. Age Ageing. 2016;45(4):448–56.CrossRefPubMedGoogle Scholar
  53. 53.
    Zissimopoulos JM, Barthold D, Brinton RD, Joyce G. Sex and race differences in the association between statin use and the incidence of Alzheimer disease. JAMA Neurol. 2017;74(2):225–32.Google Scholar
  54. 54.
    Cullen B, O’Neill B, Evans JJ, Coen RF, Lawlor BA. A review of screening tests for cognitive impairment. J Neurol Neurosurg Psychiatry. 2007;78(8):790–9.CrossRefPubMedGoogle Scholar
  55. 55.
    Brown J. The use and misuse of short cognitive tests in the diagnosis of dementia. J Neurol Neurosurg Psychiatry. 2015;86:680–5.CrossRefPubMedGoogle Scholar
  56. 56.
    Tsoi KF, Chan JC, Hirai HW, Wong SS, Kwok TY. Cognitive tests to detect dementia: a systematic review and meta-analysis. JAMA Intern Med. 2015;175(9):1450–8.Google Scholar
  57. 57.
    Carpenter CR, Bassett ER, Fischer GM, Shirshekan J, Galvin JE, Morris JC. Four sensitive screening tools to detect cognitive dysfunction in geriatric ED patients: brief Alzheimer’s screen, short blessed test, Ottawa 3DY, and the caregiver-completed AD8. Acad Emerg Med. 2011;18(4):374–84.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Salthouse TA. What cognitive abilities are involved in trail-making performance? Intelligence. 2011;39(4):222–32.CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Wicklund AH, Johnson N, Rademaker A, Weitner BB, Weintraub S. Word list versus story memory in Alzheimer disease and frontotemporal dementia. Alzheimer Dis Assoc Disord. 2006;20(2):86–92.CrossRefPubMedGoogle Scholar
  60. 60.
    Mayeux R, Saunders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer’s disease. Alzheimer’s disease centers consortium on apolipoprotein E and Alzheimer’s disease. N Engl J Med. 1998;338:506–11.CrossRefPubMedGoogle Scholar
  61. 61.
    Larner AJ. “Attended alone” sign: validity and reliability for the exclusion of dementia. Age Ageing. 2009;38:476–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Jessen F, Wiese B, Bachmann C, et al. Prediction of dementia by subjective memory impairment: effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry. 2010;67:414–22.CrossRefPubMedGoogle Scholar
  63. 63.
    Butters MA, Bhalla RK, Andreescu C, et al. Changes in neuropsychological functioning following treatment for late-life generalized anxiety disorder. Br J Psychiatry J Ment Sci. 2011;199(3):211–8.CrossRefGoogle Scholar
  64. 64.
    Butters MA, Young JB, Lopez O, et al. Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues Clin Neurosci. 2008;10(3):345–57.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Misawa T, Mizusawa H. Anti-VGKC antibody-associated limbic encephalitis/Morvan syndrome. Brain Nerve. 2010;62(4):339–45.PubMedGoogle Scholar
  66. 66.
    Chan D, Henley SM, Rossor MN, Warrington EK. Extensive and temporally ungraded retrograde amnesia in encephalitis associated with antibodies to voltage-gated potassium channels. Arch Neurol. 2007;64(3):404–10.CrossRefPubMedGoogle Scholar
  67. 67.
    Prüss H, Höltje M, Maier N, et al. IgA NMDA receptor antibodies are markers of synaptic immunity in slow cognitive impairment. Neurology. 2012;78(22):1743–53.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Zeman A, Butler C. Transient epileptic amnesia. Curr Opin Neurol. 2010;23(6):610–6.CrossRefPubMedGoogle Scholar
  69. 69.
    Emamian F, Khazaie H, Tahmasian M, et al. The association between obstructive sleep apnea and Alzheimer’s disease: a meta-analysis perspective. Front Aging Neurosci. 2016;8:78. doi:  10.3389/fnagi.2016.00078.
  70. 70.
    Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(9):2672–713.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Cordonnier C, van der Flier WM. Brain microbleeds and Alzheimer’s disease: innocent observation or key player? Brain. 2011;134(Pt 2):335–44.CrossRefPubMedGoogle Scholar
  72. 72.
    Hamilton R, Patel S, Lee EB, et al. Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology. Ann Neurol. 2010;68:535–40.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Burnett J, Dyer CB, Naik AD. Convergent validation of the Kohlman Evaluation of Living Skills as a screening tool of older adults’ ability to live safely and independently in the community. Arch Phys Med Rehabil. 2009;90(11):1948–52.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    CMA Driver’s Guide. Determining medical fitness to operate motor vehicles. 8th ed. Accessed 27 Aug 2015.
  75. 75.
    Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136–9.CrossRefPubMedGoogle Scholar
  76. 76.
    Merten TA. Short version of the Hooper visual organization test: development and validation. Clin Neuropsychol. 2002;16(2):136–44.CrossRefPubMedGoogle Scholar
  77. 77.
    Bilker WB, Hansen JA, Brensinger CM, Richard JR, Gur RE, Gur RC. Development of abbreviated nine-item forms of the Raven’s standard progressive matrices test. Assessment. 2012;19(3):354–69.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Vallar G. Spatial neglect, Balint-Homes’ and Gerstmann’s syndrome, and other spatial disorders. CNS Spectr. 2007;12(7):527–36.CrossRefPubMedGoogle Scholar
  79. 79.
    Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63(7):1168–74.CrossRefPubMedGoogle Scholar
  80. 80.
    Caine D. Posterior cortical atrophy: a review of literature. Neurocase. 2004;10(5):382–5.CrossRefPubMedGoogle Scholar
  81. 81.
    Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimers Dement. 2013;9:e1–e16.CrossRefGoogle Scholar
  82. 82.
    Crutch SJ, Lehmann M, Schott JM, Rabinovici GD, Rossor MN, Fox NC. Posterior cortical atrophy. Lancet Neurol. 2012;11(2):170–8.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA. 2015;313(19):1924–38.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Ossenkoppele R, Jansen WJ, Rabinovici GD, et al. Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. JAMA. 2015;313(19):1939–50.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioural NeurosciencesMcMaster UniversityHamiltonCanada
  2. 2.Department of Psychiatry and Behavioral SciencesUniversity of California DavisSacramentoUSA

Personalised recommendations